SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : biotech insider buys
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Tomato who wrote (162)11/17/2006 2:53:20 AM
From: idos   of 213
 
I can share my understanding on DYAX fwiw: main reason i am long there is DX-88 for treating HAE for which they have GENZ as a partner. The stock got some 50% haircut after FDA asked for more clinical trials. DX-88 should receive regulatory approval during the second half of 2008.Their competitor Jerini also had their own setback when the results from one of two pIII trails were inconclusive. Jerini also plans to ask the FDA for an expedited review, meaning the drug could be launched in 2007. My bet is that the FDA will also asl more data from Jerini.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News